Hostname: page-component-cb9f654ff-lqqdg Total loading time: 0 Render date: 2025-08-26T22:47:48.265Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic medication in learning disability Impact of audit and evidence-based medicine on quality of prescribing in a community assessment treatment unit

Published online by Cambridge University Press:  02 January 2018

Sherva E. Cooray  and
Jovanka Tolmac
Sherva E. Cooray*
Affiliation:
Parkside Health Trust, Kingsbury Community Hospital Honeypot Lane, London NW9 9QY
Jovanka Tolmac
Affiliation:
Parkside Health Trust, Kingsbury Community Hospital Honeypot Lane, London NW9 9QY
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims and method

Antipsychotic medication, an effective treatment modality in the management of psychiatric/behaviour disorders in people with learning disability, is often criticised because of poor clinical practice. Rational and judicious use, subject to evidence-based guidelines and systematic monitoring, is mandatory. A five-year clinical audit programme on the quality of prescribing for this clientele was undertaken.

Results

Significant quality improvement with minimal resource consumption was demonstrated.

Clinical implications

Clinical audit facilitates high-quality prescribing: pragmatic and economic, it can easily be integrated into routine clinical practice.

Information

Type
Original Papers
Information
Psychiatric Bulletin , Volume 22 , Issue 10 , October 1998 , pp. 601 - 604
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists

References

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.Google Scholar
Bethlem & Maudsley NHS Trust (1995) Prescribing Guidelines (2nd edn. 2nd impression), Appendix 1, pp. 21–22. London: Bethlem and Maudsley NHS Trust.Google Scholar
Brylewski, J. & Duggan, L. (1996) Antipsychotic medication for challenging behaviour in people with learning disability (Protocol). In Schizophrenia Module (eds Adams, C. E., Duggan, C., de Jesus Mari, J., et al) The Cochrane Database of Systematic Reviews (available in the Cochrane Library). London: BMJ Publishing.Google Scholar
Deb, S. & Fraser, W. (1994) The use of psychotropic medication in people with learning disability: towards rationale prescribing. Human Psychopharmacology, 9, 259–272.CrossRefGoogle Scholar
Einfeld, S. L. (1990) Guidelines for use of psychotropic medication in individuals with developmental disabilities. Australia and New Zealand Journal of Developmental Disabilities, 16, 71–73.CrossRefGoogle Scholar
Fan, T. W. (1991) Prescribing in mental handicap hospitals. British Journal of Psychiatry, 158, 282–292.Google Scholar
Foster, R. P. (1989) Neuroleptic equivalence. Pharmaceutical Journal, 243, 431–432.Google Scholar
Gravestock, S. (1994) Quality assurance for adults with mental retardation and mental health needs. In Mental Health Needs in Mental Retardation (ed. Bouras, N.), pp. 319–327. Cambridge: Cambridge University Press.Google Scholar
Gualtieri, C. T. (1990) Neuropsychiatry and Behavioural Psychopharmacology. Berlin: Springer-Verlag.Google Scholar
Harvey, R. J. & Cooray, S. E. (1993) Neuroleptic usage in a community mental handicap unit. Psychiatric Bulletin, 17, 657–660.Google Scholar
Hempel, C. G. (1961) Introduction to problems of taxonomy. In Field Studies in the Mental Disorders (ed. Zubin, J.). New York: Grune and Stratton.Google Scholar
Holbrook, J. M., Parks-Veal, P. & Mimbs, J. (1991) Clinical monitoring guidelines for neuroleptic and antidepressant drugs. Hospital Pharmacy, 26, 783–784, 787–793.Google ScholarPubMed
Joffe, R. T. & Calabrese, J. R. (eds) (1994) Anticonvulsants in Mood Disorders. New York: Marcel Dekker.Google Scholar
Matson, J. L., Kazden, A. E. & Sentore, V. (1984) Psychometric properties of the Psychopathology Instrument for Mentally Retarded Adults. Applied Research - Mental Retardation, 5, 81–89.Google Scholar
Matson, J. L., Gardner, W. I., Koe, D. A., et al (1991) A scale for evaluating emotional disorders in severely and profoundly retarded persons: Development of the Diagnostic Assessment for the Severely Handicapped (DASH) scales. British Journal of Psychiatry, 159, 404–429.Google Scholar
Paton, C. & Beer, D. (1996) Blood tests for patients prescribed psychotropics: what, when and why. Psychiatric Bulletin, 20, 356–358.Google Scholar
Royal College of Psychiatrists (1993) Consensus Statement on the Use of High Dose Antipsychotic Medication (Council Report CR26). London: Royal College of Psychiatrists.Google Scholar
Sachdev, P. S. (1991) Psychoactive drug use in an institution for intellectually handicapped persons. Medical Journal of Australia, 155, 75–79.Google Scholar
Sovner, R. (1989) Treating mentally retarded adults with psychotropic drugs: a clinical perspective. In Mental Retardation and Mental Illness (eds Fletcher, R. & Menolascino, F. J.). pp. 157–183. Lexington, MA: Lexington Books.Google Scholar
Sovner, R. (1991) Use of anticonvulsant agents for the treatment of neuropsychiatric disorders in the developmentally disabled. In Mental Retardation: Developing Pharmacotherapies (ed. Ratey, J. J.). pp. 83–106. Washington, DC: American Psychiatric Press.Google Scholar
Sovner, R. & Lowry, M. A. (1995) Pharmacological treatment of chronic behavioural problems in persons with mental retardation. In Research Pharmacological Management of Chronic Psychiatric Disorders (eds Ancill, R. J. & Lader, M. H.) in Baillière's Clinical Psychiatry, pp. 683–703. London: Baillière Tindall Harcourt.Google Scholar
Tohen, M., Castillo, J., Baldessarini, R., et al (1995) Blood dyscrasias with carbamazepine and valproate: A pharmacological study of 2228 patients at risk. American Journal of Psychiatry, 145, 339–342.Google Scholar
World Health Organization (1992) The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD–10). Geneva: WHO.Google Scholar
Wressell, S. E., Tyrer, S. P. & Berney, T. P. (1990) Reduction in antipsychotic drug dosage in mentally handicapped patients: a hospital study. British Journal of Psychiatry, 157, 101–106.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.